- Home
- REI vs LRMR Comparison
REI vs LRMR Comparison
Compare REI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REI | LRMR |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.0M | 455.8M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | REI | LRMR |
|---|---|---|
| Price | $1.51 | $3.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 3.0M | 890.8K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $307,178,072.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.17 | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $2.72 |
| 52 Week High | $2.00 | $6.42 |
Technical Indicators
Market Signals| Indicator | REI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 65.01 | 46.07 |
| Support Level | $1.23 | $3.49 |
| Resistance Level | $1.64 | $4.21 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 75.00 | 29.13 |
Price Performance
Historical ComparisonAbout REI Ring Energy Inc.
Ring Energy Inc is an independent oil and natural gas exploration and production company based in the United States. It is engaged in oil and natural gas development, production, acquisition, and exploration activities, currently focused on the Permian Basin of Texas. The company's drilling operations target the oil and liquids-rich producing formations in the Northwest Shelf and the Central Basin Platform, in the Permian Basin in Texas.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.